Targeting RPRD1B overcomes chemoresistance in gastric cancer by suppressing the TOPBP1-mediated DNA damage repair pathway
Cellular Oncology · 02.08.2026 · 49 (3)
DOI: 10.1007/s13402-026-01227-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 02.08.2026. Verfasst von Jian Sheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Tsinghua University, Beijing, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Drug Resistance, Neoplasm, DNA Repair, DNA-Binding Proteins. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Bureau of Jiaxing city, Science and Technology special fund of Hainan Province, Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Despite the widespread adoption of 5-fluorouracil (5-FU)-based regimens as first-line therapy for gastric cancer, a substantial number of patients develop innate or acquired resistance, highlighting the critical need to identify its underlying molecular drivers. RPRD1B (CREPT), a gene frequently overexpressed in GC, has been clinically associated with advanced tumor stage and poor prognosis. Functionally, RPRD1B promotes aggressive tumorigenic phenotypes by accelerating cell-cycle progression, potentiating proliferative signaling, and enhancing the migratory and invasive capacities of cancer cells. However, its functional role in mediating chemotherapy resistance has not been elucidated.
Methods
We established 5-FU-resistant gastric cancer cell lines (from AGS/MGC803 parents via stepwise drug exposure) to study RPRD1B’s mechanism, and developed an AAV-based system to therapeutically target RPRD1B to overcome 5-FU resistance.
Results
In this study, we demonstrated that GC patients with high tumor expression of RPRD1B (CREPT) exhibited a poor response to 5-fluorouracil (5-FU)-based chemotherapy. Furthermore, RPRD1B expression was positively correlated with the expression of TOPBP1, a critical DNA damage response and repair effector. Mechanistically, RPRD1B transcriptionally upregulates TOPBP1 by recruiting RNA polymerase II to its promoter, thereby enhancing DNA damage repair. Using an AAV-delivered shRNA to knockdown RPRD1B in a nude mouse xenograft model, we effectively overcame 5-FU resistance in gastric tumors in vivo.
Conclusions
Our findings identify RPRD1B as a promising therapeutic target for reversing chemoresistance in gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Tsinghua University, Beijing, China.
- Department of Research and Teaching, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
- Department of Surgical Oncology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
- Department of Pathology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
- Department of Pathology, First Hospital of Tsinghua University, Jiaxing, China.
Förderung
- Science and Technology Bureau of Jiaxing city
- Science and Technology special fund of Hainan Province
- Zhejiang Provincial Natural Science Foundation of China
- Starlit South Lake Leading Elite Program of Jiaxing city
- Zhejiang Provincial Medical and Health Science and Technology Program
Zitieren
APA
Sheng, J., Li, J., Cao, C., Liu, X., He, C., Fei, M., Wu, B., Li, X., Hu, C., Liu, S., & Lv, Y. (2026). Targeting RPRD1B overcomes chemoresistance in gastric cancer by suppressing the TOPBP1-mediated DNA damage repair pathway. Cellular Oncology, 49(3). https://doi.org/10.1007/s13402-026-01227-0
Vancouver
Sheng J, Li J, Cao C, Liu X, He C, Fei M, et al. Targeting RPRD1B overcomes chemoresistance in gastric cancer by suppressing the TOPBP1-mediated DNA damage repair pathway. Cellular Oncology. 2026;49(3). doi:10.1007/s13402-026-01227-0
BibTeX
@article{Sheng2026,
author = {Sheng, Jian and Li, Jianghua and Cao, Chenxi and Liu, Xiaorong and He, Chunhua and Fei, Mingjian and Wu, Bin and Li, Xiangli and Hu, Chundong and Liu, Shumin and Lv, Yahui},
title = {Targeting RPRD1B overcomes chemoresistance in gastric cancer by suppressing the TOPBP1-mediated DNA damage repair pathway},
journal = {Cellular Oncology},
year = {2026},
volume = {49},
number = {3},
doi = {10.1007/s13402-026-01227-0}
}
EUVIMED